JMP Securities Maintains Market Outperform on Aura Biosciences, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Aura Biosciences (NASDAQ:AURA) but reduced the price target from $21 to $19.

November 10, 2023 | 7:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities reaffirmed a Market Outperform rating on Aura Biosciences, while lowering the price target from $21 to $19, indicating a positive outlook but with a reduced growth expectation.
The affirmation of the Market Outperform rating suggests that JMP Securities remains optimistic about Aura Biosciences' prospects. However, the reduction in the price target may reflect a reassessment of the growth potential or risks associated with the company, which could lead to a neutral short-term impact on the stock as investors digest the mixed signals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100